Department of Intensive Care, CUB-Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Department of Infectious Diseases, CUB-Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.02534-17. Print 2018 Sep.
Augmented renal clearance is commonly observed in septic patients and may result in insufficient β-lactam serum concentrations. The aims of this study were to evaluate potential correlations between drug concentrations or total body clearance of β-lactam antibiotics and measured creatinine clearance and to quantify the need for drug dosage adjustments in septic patients with different levels of augmented renal clearance. We reviewed 256 antibiotic measurements (512 drug concentrations) from a cohort of 215 critically ill patients who had a measured creatinine clearance of ≥120 ml/min and who received therapeutic drug monitoring of meropenem, cefepime, ceftazidime, or piperacillin from October 2009 until December 2014 at Erasme Hospital. Population pharmacokinetic (PK) analysis of the data was performed using the Pmetrics software package for R. Fifty-five percent of drug concentrations showed insufficient β-lactam serum concentrations to treat infections due to There were significant, yet weak, correlations between measured creatinine clearance and trough concentrations of meropenem ( = -0.21, = 0.01), trough concentrations of piperacillin ( = -0.28, = 0.0071), concentrations at 50% of the dosage interval ( = -0.41, < 0.0001), and total body clearance of piperacillin ( = 0.39, = 0.0002). Measured creatinine clearance adequately explained changes in drug concentrations in population pharmacokinetic models for cefepime, ceftazidime, and meropenem but not for piperacillin. Therefore, specific PK modeling can predict certain β-lactam concentrations based on renal function but not on absolute values of measured creatinine clearance, easily available for clinicians. Currently, routine therapeutic drug monitoring is required to adjust daily regimens in critically ill patients receiving standard dosing regimens.
增强的肾清除率在脓毒症患者中很常见,可能导致β-内酰胺类药物的血清浓度不足。本研究旨在评估β-内酰胺类抗生素的药物浓度或全身清除率与测量的肌酐清除率之间的潜在相关性,并量化不同程度增强的肾清除率的脓毒症患者药物剂量调整的需求。我们回顾了 2009 年 10 月至 2014 年 12 月在 Erasme 医院接受美罗培南、头孢吡肟、头孢他啶或哌拉西林治疗的 215 名危重病患者的 256 次抗生素测量(512 个药物浓度),这些患者的肌酐清除率≥120ml/min,并进行了治疗药物监测。使用 R 中的 Pmetrics 软件包对数据进行群体药代动力学(PK)分析。由于 55%的药物浓度显示β-内酰胺类药物的血清浓度不足以治疗感染,因此存在不足。美罗培南的谷浓度(= -0.21,= 0.01)、哌拉西林的谷浓度(= -0.28,= 0.0071)、剂量间隔 50%时的浓度(= -0.41,< 0.0001)和哌拉西林的全身清除率(= 0.39,= 0.0002)之间存在显著但较弱的相关性。在头孢吡肟、头孢他啶和美罗培南的群体药代动力学模型中,测量的肌酐清除率可以很好地解释药物浓度的变化,但在哌拉西林中则不能。因此,基于肾功能而不是临床医生容易获得的测量肌酐清除率的绝对值,可以使用特定的 PK 模型预测某些β-内酰胺类药物的浓度。目前,需要进行常规治疗药物监测,以调整接受标准剂量方案的危重病患者的日常治疗方案。